© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

Asia Pacific

  • New Oriental Education & Technology Group, one of China’s largest private education companies, has kicked off bookbuilding for a Hong Kong secondary listing worth around $1.4bn.
  • The announcement this week of two acquisitions involving European and emerging market companies has cheered loans bankers who have been missing big M&A tickets because of the Covid-19 pandemic.
  • China Merchants Bank has sold its first mortgage backed securitization (RMBS) transaction with an international rating. The foreign demand helped with a smooth bookbuilding process, despite a less than favourable market backdrop for the outing.
  • Formosa Plastics Corp has shortlisted six banks to arrange a multi-tranche financing for its Vietnam business.
  • Gansu Provincial Highway Aviation Tourism Investment Group Co found lacklustre support for its $300m bond on Tuesday after its pricing strategy deterred investors from joining the deal.
  • Chinese data centre operator GDS Holdings has pocketed HK$12.9bn ($1.67bn) from its secondary offering on Hong Kong’s stock exchange.
  • Korea Land & Housing Corp has broken a six-year absence from the dollar debt market to raise $300m from a social bond.
  • Krafton, a popular South Korean video game developer, has mandated banks for its 2021 IPO.
  • China’s ecological and financial regulators have jointly published guidelines around climate change-related financing and investment.
  • JP Morgan has rejigged the leadership of its Asia Pacific capital markets businesses, promoting Francesco Lavatelli to the helm of the ECM team.
  • Asian loans bankers are calling for relaxed restrictions on green and sustainability-linked loans, hoping for more business opportunities from the sector. But this approach could harm the development of the market in the long-term.
  • RemeGen, a Chinese biopharmaceutical company, has rolled out a Hong Kong IPO that could be worth up to HK$3.99bn ($514.5m).